Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Toronto Stock Exchange  >  Cardiome Pharma Corp    COM   CA14159U3010

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

CARD PHARM : Cardiome to Hold Conference Call to Discuss First Quarter Results and Corporate Update

share with twitter share with LinkedIn share with facebook
share via e-mail
07/25/2011 | 11:56pm CET

Vancouver, Canada, July 25th, 2011 ? Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced it will hold a conference call to discuss Q1-2011 financial results and to provide a corporate update.

To access the conference call, please dial 416-340-2217 or 866-696-5910 and reference conference 6435784 . There will be a separate dial-in line for analysts on which we will respond to questions at the end of the call. The webcast can be accessed through Cardiome?s website at www.cardiome.com .

Webcast and telephone replays of the conference call will be available approximately two hours after the completion of the call through August 26th, 2011. Please dial 905-694-9451 or 800-408-3053 and enter code 7372760# to access the replay.

About Cardiome Pharma Corp.

Cardiome Pharma Corp. is a product-focused drug development company dedicated to the advancement and commercialization of novel treatments for disorders of the heart and circulatory system. Cardiome is traded on the NASDAQ Global Market (CRME) and the Toronto Stock Exchange (COM). For more information, please visit our web site at www.cardiome.com.

For Further Information:  

Cardiome Investor Relations  (604) 676-6993 or Toll Free: 1-800-330-9928 Email: [email protected]

Forward-Looking Statement Disclaimer

Certain statements in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words ?believe?, ?may?, ?plan?, ?will?, ?estimate?, ?continue?, ?anticipate?, ?intend?, ?expect? and similar expressions. Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments expressed or implied by such forward-looking statements or information. Such factors include, among others, our stage of development, lack of product revenues, additional capital requirements, risk associated with the completion of clinical trials and obtaining regulatory approval to market our products, the ability to protect our intellectual property, dependence on collaborative partners and the prospects for negotiating additional corporate collaborations or licensing arrangements and their timing. Specifically, certain risks and uncertainties that could cause such actual events or results expressed or implied by such forward-looking statements and information to differ materially from any future events or results expressed or implied by such statements and information include, but are not limited to, the risks and uncertainties that: we may not be able to successfully develop and obtain regulatory approval for vernakalant (iv) or vernakalant (oral) in the treatment of atrial fibrillation or any other current or future products in our targeted indications; our future operating results are uncertain and likely to fluctuate; we may not be able to raise additional capital; we may not be successful in establishing additional corporate collaborations or licensing arrangements; we may not be able to establish marketing and sales capabilities and the costs of launching our products may be greater than anticipated; we rely on third parties for the continued supply and manufacture of vernakalant (iv) and vernakalant (oral) and we have no experience in commercial manufacturing; we may face unknown risks related to intellectual property matters; we face increased competition from pharmaceutical and biotechnology companies; and other factors as described in detail in our filings with the Securities and Exchange Commission available at www.sec.gov and the Canadian securities regulatory authorities at www.sedar.com. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward-looking statements and information to reflect subsequent events or circumstances, except as required by law.

share with twitter share with LinkedIn share with facebook
share via e-mail
01/10 CARDIOME PHARMA : to Participate in the Cantor Fitzgerald Antibiotics Summit
2017 CARDIOME PHARMA : Announces XYDALBA Treatment and Patient Experience Presentatio..
2017 CARDIOME PHARMA : Highlights Partner SteadyMed’s Agreement with the FDA on..
2017 CARDIOME PHARMA : Highlights Partner SteadyMed's Agreement With FDA On Pathway T..
2017 CARDIOME PHARMA : Announces Xydalba™ Treatment And Patient Experience Pres..
2017 CARDIOME PHARMA : to Present at the 29th Annual Piper Jaffray Healthcare Confere..
2017 CARDIOME PHARMA : Reports Third Quarter 2017 Financial Results
2017 CARDIOME PHARMA CORP : Cardiome Pharma Corp. to Host Earnings Call
2017 CARDIOME PHARMA : To Hold Third Quarter 2017 Financial Results Conference Call O..
2017 CARDIOME PHARMA : Announces Commercial Launch of Xydalba(TM) in Three New Europe..
More news
News from SeekingAlpha
2017 YOUR DAILY PHARMA SCOOP : Ultragenyx Sells Voucher, Regeneron Announces Collabor..
2017 Cardiome Pharma's (CRME) CEO William Hunter on Q3 2017 Results - Earnings Cal..
2017 Cardiome Pharma misses by $0.02, misses on revenue
2017 Notable earnings after Tuesday?s close
2017 3 THINGS IN BIOTECH YOU SHOULD LEARN : September 4, 2017
Financials ( CAD)
Sales 2017 33,5 M
EBIT 2017 -27,6 M
Net income 2017 -33,9 M
Debt 2017 -
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales 2017 1,99x
Capi. / Sales 2018 1,34x
Capitalization 66,5 M
Duration : Period :
Cardiome Pharma Corp Technical Analysis Chart | COM | CA14159U3010 | 4-Traders
Technical analysis trends CARDIOME PHARMA CORP
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 3
Average target price 8,91  CAD
Spread / Average Target 364%
EPS Revisions
William L. Hunter President, Chief Executive Officer & Director
William James O'Shea Chairman
Sheila M. Grant Chief Operating Officer
Justin A. Renz Chief Financial Officer
Richard M. Glickman Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
BIOGEN6.37%71 659
CSL LIMITED0.51%51 198
GRIFOLS SA6.73%20 235